DRMA

Dermata Therapeutics, Inc. DRMA

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$173.5K total
GEODE CAPITAL MANAGEMENT, LLC
$26.1K-58.2%
WELCH & FORBES LLC
$25.8K0.0%
STATE STREET CORP
$24.2KNew
UBS Group AG
$21.7K-49.6%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$20.6KNew
XTX Topco Ltd
$19.1KNew
BOOTHBAY FUND MANAGEMENT, LLC
$15.5K0.0%
Advisory Alpha, LLC
$12.9KNew
Tower Research Capital LLC (TRC)
$5.0K+439.1%
MCF Advisors LLC
$2.2K0.0%
BARCLAYS PLC
$348New
SBI Securities Co., Ltd.
$1300.0%
HIGHLINE WEALTH PARTNERS LLC
$34New
MORGAN STANLEY
$3New
Virtu Financial LLC
$0New
See all 15 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/DRMA

Earnings Per Share

13fpro.ai/company/DRMA

Loading ratio trend…

DRMA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Dermata Therapeutics, Inc. (DRMA): stock profile, AI score and financials

Dermata Therapeutics, Inc. (DRMA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. DRMA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of DRMA by reported 13-F value include GEODE CAPITAL MANAGEMENT, WELCH & FORBES, STATE STREET, based on the most recent SEC filings. DRMA trades on the Nasdaq exchange and files with the SEC under CIK 1853816. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DRMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Dermata Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1853816 →